Microdose Journal

Scientific News, Journal Papers, Studies for Microdosing for Mental Health

Menu
  • About MicrodoseJournal.com
  • Conferences
  • Contact
  • Find Psychedelic Therapy Providers:
  • News
  • Psychedelic Studies & Research Centers
  • Retreats
  • Scientific Papers
  • Video
Menu

Psilocybin-assisted therapy for depression: How do we advance the field?

Posted on January 5, 2020 by Research

Aust N Z J Psychiatry. 2019 Nov 22:4867419888575. doi: 10.1177/0004867419888575. [Epub ahead of print]

Meikle SE1, Liknaitzky P2, Rossell SL3, Ross M4, Strauss N5, Thomas N2,3, Murray G2,3, Williams M6, Castle DJ7,8.

Author information

1Melbourne School of Psychological Science, The University of Melbourne, Melbourne, VIC, Australia.2School of Psychology, Deakin University, Burwood, VIC, Australia.3Centre for Mental Health, Swinburne University, Hawthorn, VIC, Australia.4Department of Psychosocial Cancer Care and Palliative Medicine. St Vincent’s Hospital Melbourne, VIC, Australia.5Honorary Research Fellow with Psychiatry, University of Melbourne, Millswyn Psychiatric Clinic, South Yarra, VIC, Australia.6Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.7Department of Psychiatry, St Vincent’s Hospital, Fitzroy, VIC, Australia.8Department of Psychiatry, The University of Melbourne, Melbourne, VIC, Australia.

Abstract

In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment, including clarification of the profile of people most likely to benefit and those who might experience adverse effects, longer-term outcomes and the role of psychotherapeutic input alongside the drug itself. There are also opportunities to understand better, the neurobiology underpinning its effects.

KEYWORDS:

Psilocybin; depression; psychedelicsPMID: 31752499 DOI: 10.1177/0004867419888575

1 thought on “Psilocybin-assisted therapy for depression: How do we advance the field?”

  1. Luc @ Psychedelicinsights says:
    January 18, 2020 at 4:35 pm

    The reality is the offer of psilocybin to benefit individuals is available in Amsterdam. Retreats and 1 day sessions can truly have an effect on participants feelings and outlook on life. Psychedelic assisted therapy requires skill and experience…

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

About This Site

The Microdose Journal provides scientific studies and articles relating to the phenomenon of microdosing for the improvement of mental health.  It is also a resource for major study centers, conferences, and therapy centers that utilize psychedelics.

Recent Posts

  • A Review of LSD Treatment in Alcoholism
  • Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
  • The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
  • The ethics of psychedelic research in disorders of consciousness
  • Psychedelic Support
  • Santa Cruz, California City Council Approves Decriminalization Measure Measure for Psychedelics
  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
  • Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions
  • Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
  • The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving
© 2023 Microdose Journal | Powered by Minimalist Blog WordPress Theme